CClinicalTrials.gg
Status unknownNCT03488888Updated Apr 5, 2018

PEC Block II in Mammoplasty Surgeries

An interventional study of Normal Saline 0,9% and Bupivacaine in Mammaplasty, Anesthesia, Conduction and Analgesia, sponsored by Federal University of São Paulo. Status unknown at 1 site in Brazil. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-05.

Sponsored by Federal University of São Paulo · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Breast augmentation surgery is the top cosmetic surgery in USA with more then 300.000 cases performed annually. Pain is a common complications of the procedure accompanied of dyspnea and nausea due to the surgical manipulation.

Several anesthetic techniques were developed with the objective of providing optimal surgical conditions together with enhanced recovery and post-op pain management.

Pectoralis major block was first described in 2011 by Blanco in female patients undergoing oncologic procedures in the anterior thoracic wall.

The investigators hypothesized if the Pectoralis Major block combined with general anesthesia standard techniques could be beneficial in improving pain scores and opioid consumption during post operative period of patients undergoing breast augmentation surgery.

Read the detailed description

Patients undergoing Breast Augmentation Mammoplasty were submitted to laryngeal mask placement after anesthetic induction with Fentanyl 3ucg/kg , Propofol 2mg/kg and Atracurium 0,5mg/kg and surgery was performed under standard surgical practices.

Before the surgical incision patients were randomized either to receive a Bilateral Pectoralis Major Block(PEC I and II) with Bupivacaine 0,25% with Epinephrine or to receive a placebo block with Normal Saline 0,9%.

After the procedure all patients received a intravenous patient-controlled-analgesia pump device with morphine.

Pain and opioid consumption were assessed with a pain score assessment tool and assessment of the pump administration dosage history.

No NSAIDs or alpha 2 agonist drugs were administered during or after the procedure.

The maintenance of anesthesia was performed with Propofol and Remifentanil Total intravenous anesthesia(TIVA) models in a standardized fashion. Micromanagement of anesthetic drugs was performed by the assistant anesthesiologist physician.

02

Conditions studied

  • Mammaplasty
  • Anesthesia, Conduction
  • Analgesia
  • Analgesia, Patient-Controlled

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Female
  • Above 18 years old
  • Elective Surgery
  • American Society of Anesthesia(ASA) Class I up to III

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Acute Coronary Syndrome
  • History of Arrhythmia
  • Functional Class New York Heart Association(NYHA) III or IV
  • Previous thoracic/breast surgery
  • History of Chronic Pain
  • Neuromuscular disease
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Sham comparator
    Normal Saline

    General Anesthesia + Bilateral Pectoral injection of Normal Saline 0,9% 1. Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles 2. Injection of 10 mL normal saline 0,9% between muscles lateral to the thoracoacromial artery. 3. Visualization of Pectoralis menor and Serratil Muscles 3- Injection of 20 mL of normal saline 0,9% between Pectoralis minor and serratil muscles 4-Visualize the hydrodissection performed by the solution

    Drug: Normal Saline 0,9%

  • Experimental
    Bupivacaine

    General Anesthesia + Bilateral Pectoral injection of 30 mL of 0.25% Bupivacaine 1. Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles 2. Injection of 10 mL of local anesthetic between muscles lateral to the thoracoacromial artery. 3. Visualization of Pectoralis minor and Serratil Muscles 3- Injection of 20 mL of local anesthestic between Pectoralis minor and Serratil muscles 4-Visualize the hydrodissection performed by the solution

    Drug: Bupivacaine

Interventions

  • DrugNormal Saline 0,9%

    Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%

  • DrugBupivacaine

    Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution

    Also known as: Brand: Cristália

05

What researchers measure

Primary outcomes

  1. Pain Score

    Patients will be actively questioned about their pain score assessment

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Opioid Consumption

    The total amount of opioid will be evaluated using an Patient Controlled Analgesia Pump

    Time frame: 1 hour, 2 hours, 4 hours, 6 hours, 12 hours and 24 hours after surgery

06

Study locations

1 of 1 sites recruiting
  • Federal University of Sao Paulo
    São Paulo, Sao Paulo 04024002, Brazil
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03488888
Lead sponsor
Federal University of São Paulo
Responsible party
Leonardo Henrique Cunha Ferraro (Professor, Federal University of São Paulo) — Principal investigator
First posted
Apr 5, 2018
Start date
Nov 3, 2017
Primary completion
Dec 1, 2018 (estimated)
Completion
Jan 1, 2019 (estimated)
Last update
Apr 5, 2018

Study contacts

Paulo Cesar Castello Branco, MD
Contact
pccastellobranco@yahoo.com.br
+55 (11) 5571-2746
Paulo Cesar Castello Branco, MD
principal investigator · Federal University of São Paulo

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion